Accessibility Menu
Universal Ibogaine logo

Universal Ibogaine(OTC) IBOGF

Market Cap$7.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-65%
5 YearN/A
1 Year+23%
1 Month+2%
$0.03
+9.58%
+0.00Today
Universal Ibogaine last closing stock price
MetricPriceDate
Last closeUSD 0.032026-07-29
Universal Ibogaine stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.14%USD 0.032026-07-22
1 month+1.54%USD 0.032026-06-29
3 month-28.92%USD 0.042026-04-30
Year to date+696.97%USD 0.002025-12-31
1 year+22.9%USD 0.022025-07-29
3 year+134.82%USD 0.012023-07-26
Since inception-65.26%USD 0.082022-03-01

Universal Ibogaine Financials at a Glance

Market Cap

$7.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$1.54M

Net Income (TTM)

-CA$1.65M

EPS (TTM)

-$0.00

P/E Ratio

-7.51

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.03

Volume

54,381

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.00 - $0.35

Estimated Earnings Date

Jan 9, 2026

IBOGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Universal Ibogaine

Universal Ibogaine Inc. is a life sciences company dedicated to developing and operating addiction treatment centers across Canada. The organization is also preparing to initiate clinical trials to explore the therapeutic potential of ibogaine for addiction treatment.

Products and Services
  • Development of addiction treatment centers in Canada
  • Research on ibogaine's therapeutic applications
  • Clinical trials aimed at addiction recovery solutions
Growth Outlook
  • Recent revenue growth from CAD 42,267 to CAD 700,918 in Q3 2025
  • Operating income improved significantly, reaching CAD 254,812 in Q3 2025
  • Expansion plans for additional treatment centers across Canada
Financial Highlights
  • Market capitalization stands at approximately CAD 8.15 million
  • Trailing twelve months (TTM) revenue of CAD 1.5 million
  • Cash and cash equivalents of CAD 127,746 as of Q3 2025
Universal Ibogaine Inc. operates in the biotechnology sector, focusing on innovative solutions for addiction treatment. The company has shown promising revenue growth, with a notable increase in quarterly revenue, indicating a positive trend in its business model. The operating income has also improved, reflecting better management of expenses and operational efficiency. With a market capitalization of approximately CAD 8.15 million, the company is positioned for potential growth as it expands its treatment facilities and continues its research initiatives. The cash position, while modest, supports ongoing operations and development efforts. Overall, Universal Ibogaine Inc. presents an intriguing opportunity in the healthcare sector, particularly for those interested in innovative addiction treatment solutions.
AI Generated • Jul 22, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Nicholas Peter Karos

Website

www.universalibogaine.com

Headquarters

Calgary, AB T2P 4H2, CA

IBOGF Financials

Key Financial Metrics (TTM)

Gross Margin

9.01%

Operating Margin

24.83%

Net Income Margin

-34.56%

Return on Equity

-120.71%

Return on Capital

8.75%

Return on Assets

-9.25%

Earnings Yield

-13.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

274.83M

Volume

54.38K

Avg. Volume

373.88K

Financials (TTM)

Gross Profit

CA$1.18M

Operating Income

CA$189.39K

EBITDA

-CA$1.20M

Operating Cash Flow

-CA$964.68K

Capital Expenditure

-CA$253.52K

Free Cash Flow

-CA$1.22M

Cash & ST Invst.

CA$127.75K

Total Debt

CA$2.57M

Universal Ibogaine Performance Analysis

Universal Ibogaine annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-07-31CAD 0N/A
20222022-07-31CAD 843,715N/A
20232023-07-31CAD 767,615-9.0%
20242024-07-31CAD 1,715,149123.4%
Universal Ibogaine sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-01-31N/A
Q32023-04-30937.9%
Q22025-01-31N/A
Q32025-04-3088.6%
Universal Ibogaine annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-07-31CAD -0.02N/A
20222022-07-31CAD -0.0483.9%
20232023-07-31CAD -0.01-79.1%
20242024-07-31CAD -0.01-30.1%
Universal Ibogaine sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-01-316.8%
Q32023-04-3039.0%
Q22025-01-31N/A
Q32025-04-3080.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

CA$700.92K

N/A

Gross Profit

CA$700.92K

N/A

Gross Margin

100.00%

N/A

Market Cap

$7.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.03M

N/A

Employees

7

N/A

Net Income

-CA$66.20K

+92.1%

EBITDA

CA$52.89K

+107.3%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

CA$127.75K

-81.8%

Total Debt

CA$2.57M

+11.9%

Accounts Receivable

CA$608.26K

+421.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$1.72M

+130.2%

Short Term Debt

CA$848.92K

-45.3%

Return on Assets

-9.25%

N/A

Return on Invested Capital

13.35%

N/A

Free Cash Flow

-CA$110.37K

+81.4%

Operating Cash Flow

-CA$110.37K

+75.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRTXGalera Therapeutics, Inc.
$15.62+0.32%
AAGHAmerica Great Health
$0.00+0.00%
HESGHealth Sciences Group, Inc.
$0.00+0.00%
APLIFAppili Therapeutics Inc
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About IBOGF

What is the current price of Universal Ibogaine?

Universal Ibogaine is trading at $0.03 per share.

What is the 52-week range for Universal Ibogaine?

Over the past 52 weeks, Universal Ibogaine has traded between $0.00 and $0.35.

How much debt does Universal Ibogaine have?

As of the most recent reporting period, Universal Ibogaine reported total debt of CA$1.86M.

How much cash does Universal Ibogaine have on hand?

Universal Ibogaine reported CA$92.48K in cash and cash equivalents in its most recent financial results.

What is Universal Ibogaine’s dividend yield?

Universal Ibogaine does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services